|
Source | Allograft | Time from transplant | Demographic risk factor | Presenting feature | Diagnostic test | Treatment | Outcome |
|
Said et al. [14] | Kidney | 48 days | Cadaveric donor from South Asia | SHS | BAL examination | Oral and rectal albendazole/ivermectin | Death |
Kidney | 90 days | Cadaveric donor from South Asia | SHS | BAL examination | Oral and rectal albendazole/ivermectin | Death |
Kidney | 92 days | SHS | BAL examination | Oral and rectal albendazole/ivermectin | Death |
|
Huston et al. [15] | Kidney | 90 days | Cadaveric donor from Puerto Rico | Fever and respiratory distress | BAL examination | Oral and rectal albendazole/ivermectin Trial of veterinary ivermectin (after case-specific FDA approval) × 3 doses | Successful treatment |
|
Hoy et al. [16] | Kidney Kidney | 33 days 64 days | None | Diarrhea and fever Cough and fever | Stool analysis Urine analysis | Thiabendazole × 5 d Thiabendazole × 5 d | Death Successful treatment |
|
Patel et al. [17] | Intestine | 9 months | Donor from Honduras | Nausea/vomiting and abdominal discomfort Fevers | Small bowel and colon endoscopic biopsy BAL examination | Oral ivermectin/thiabendazole and rectal ivermectin × 10 d | Successful treatment initially but died later during the same hospitalization due to acinetobacter bacteremia |
|
Ben-Youssef et al. [18] | Pancreas | 49 days | Donor was immigrant to the USA | Hematuria and epigastric pain | Duodenal biopsy | Oral thiabendazole/ivermectin × 7 d | Successful treatment |
|
Brügemann et al. [12] | Heart | 6 weeks | Donor from Surinam | Abdominal pain and rash | Skin biopsy | Oral ivermectin × 15 d Oral albendazole × 10 d | Successful treatment |
|
Rodriguez- Hernandez et al. [19] | Liver | 2.5 months | Donor from Ecuador | Anorexia and diarrhea | Sputum and stool sample examination | Oral albendazole/ivermectin × 2 weeks, then ivermectin only × 2 weeks, followed by intermittent ivermectin secondary prophylaxis | Successful treatment |
|